ArticleFrontiers in physiology2025
Analysis of hub genes temporal dynamics in cardiac ischemia/reperfusion injury: a bioinformatics and experimental study.
Article in Frontiers in physiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Myocardial ischemia/reperfusion injury (MIRI) remains a major global health issue with rising morbidity and mortality. Blood flow restoration can worsen damage to oxygen-deprived cardiac tissue. This research aimed to identify hub genes linked to MIRI across various reperfusion stages, offering potential diagnostic indicators and therapeutic targets. Methods: Differentially expressed genes (DEGs) at 6, 24, and 72 h post-reperfusion based on the GSE160516 dataset via GEO2R were identified, and these genes were further analyzed using the DAVID database and online platforms for Gene Ontology Kyoto Encyclopedia of Genes and Genomes (KEGG) and Disease Ontology (DO) enrichment. Protein-protein interaction networks were constructed using STRING and visualized with Cytoscape, and the Degree algorithm within the CytoHubba plug-in identified the top ten hub genes at each time point. Additional analyses included miRNA-hub gene prediction, transcription factor-hub gene regulation, and drug-hub gene interactions via miRDB, TRRUST and DGIdb platforms. Receiver operating characteristic (ROC) curve analysis and immune cell infiltration assessment were performed using online analytical tools and CIBERSORT. Finally, an oxygen-glucose deprivation/reperfusion (OGD/R) model in HL-1 mouse cardiomyocytes and external datasets validated the expression of hub genes. Results: Totally, 341, 399 and 431 DEGs at 6, 24, and 72 h post-reperfusion were screened, enriched in functions, such as inflammatory pathways, cytokine-receptor interactions, and immune or inflammatory-related diseases. Degree algorithm analysis identified the top ten hub genes (Il1b, Cxcl2, Cd44, etc.) at 6h, (Il1b, Il6, Fn1, etc.), at 24 h and (Fcgr3, Ccl2, Cd68, etc.) at 72 h. Most hub genes showed notable interactions with specific microRNAs (mmu-let-7c-1-3p, mmu-miR-466L-3p), the transcription factor Nfkb1, and drugs with the highest drug-gene interaction scores (EMAPTICAP PEGOL, CARLUMAB, Compound 27 [PMID: 19854648]). ROC curve analyses demonstrated high diagnostic potential (AUC 0.889-1.000; sensitivity 100%; specificity 66.67%-100%) and immune infiltration analysis indicated increased resting dendritic cells and decreased neutrophils. Validation in HL-1 OGD/R models and external datasets confirmed elevated mRNA expression of Serpine1, Ccl2, Il6, and Fn1 at various reperfusion stages. Conclusion: Analysis across multiple datasets and HL-1 cell experimental models revealed four significantly altered genes-Serpine1, Ccl2, Il6 and Fn1-indicating their potential targets for MIRI.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.